| Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Co.'s KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. Co. also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. Co.'s clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. Co. has several discovery programs, including a preclinical program for a KRAS G12D inhibitor. We show 34 historical shares outstanding datapoints in our coverage of MRTX's shares outstanding history.|
Understanding the changing numbers of MRTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MRTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MRTX by allowing them to research MRTX shares outstanding history
as well as any other stock in our coverage universe.